Nabriva Therapeutics (NASDAQ:NBRV) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com started coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV) in a report released on Sunday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Nabriva Therapeutics Price Performance

NASDAQ NBRV opened at $0.00 on Friday. The company has a quick ratio of 0.52, a current ratio of 0.85 and a debt-to-equity ratio of 0.12. The company has a market capitalization of $9,604.50, a PE ratio of 0.00 and a beta of 1.53. Nabriva Therapeutics has a 52-week low of $1.22 and a 52-week high of $8.45.

About Nabriva Therapeutics

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration.